相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
Jeffrey S. Berger et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data
Olivia S. Costa et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Polypharmacy, Adverse Outcomes, and Treatment Effectiveness in Patients ≥75 With Atrial Fibrillation
Nemin Chen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy
Amgad Mentias et al.
STROKE (2020)
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation
Kazuhiko Kido et al.
ANNALS OF PHARMACOTHERAPY (2019)
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
Margarita Kushnir et al.
LANCET HAEMATOLOGY (2019)
Obesity and Polypharmacy among African American Older Adults: Gender as the Moderator and Multimorbidity as the Mediator
Shervin Assari et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation
Ralf E. Harskamp et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists
Lisa Eggebrecht et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2019)
Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
Brandon K. Martinez et al.
PHARMACOTHERAPY (2019)
Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
Eric D. Peterson et al.
AMERICAN HEART JOURNAL (2019)
Relation of Obesity to New-Onset Atrial Fibrillation and Atrial Flutter in Adults
Andrew J. Foy et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data
Eric M. Ammann et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2018)
Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation
Fahad Shaikh et al.
CURRENT CARDIOLOGY REPORTS (2018)
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
Stefan Willmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices
Jose Francisco Kerr Saraiva
CARDIOLOGY AND THERAPY (2018)
What is polypharmacy? A systematic review of definitions
Nashwa Masnoon et al.
BMC GERIATRICS (2017)
Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care
Deirdre A. Lane et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
A dataset quantifying polypharmacy in the United States
Katie J. Quinn et al.
SCIENTIFIC DATA (2017)
The impact of body weight on rivaroxaban pharmacokinetics
Sarah J. Barsam et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)
Somasekhara R. Balla et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience
Shaban Mohammed et al.
JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH (2017)
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation
Jonathan P. Piccini et al.
CIRCULATION (2016)
Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults
Anat Berkovitch et al.
AMERICAN HEART JOURNAL (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2016)
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K. Martin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Trends in Prescription Drug Use Among Adults in the United States From 1999-2012
Elizabeth D. Kantor et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Risk of systemic emboli in AF
Gregory B. Lim
Nature Reviews Cardiology (2015)
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
Peter C. Austin et al.
STATISTICS IN MEDICINE (2015)
Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
Mikhail S. Dzeshka et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2015)
Validity of a Claims-Based Diagnosis of Obesity Among Medicare Beneficiaries
Jennifer T. Lloyd et al.
EVALUATION & THE HEALTH PROFESSIONS (2015)
Comparison of the Frequency of Atrial Fibrillation in Young Obese Versus Young Nonobese Men Undergoing Examination for Fitness for Military Service
Morten Schmidt et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Coding of obesity in administrative hospital discharge abstract data: accuracy and impact for future research studies
Billie-Jean Martin et al.
BMC HEALTH SERVICES RESEARCH (2014)
Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study
Gebrehiwot Teklay et al.
THROMBOSIS JOURNAL (2014)
Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study
Deniz Karasoy et al.
EUROPACE (2013)
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
Danijela Gnjidic et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2012)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
An automated database case definition for serious bleeding related to oral anticoagulant use
Andrew Cunningham et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation The WHS (Women's Health Study)
Usha B. Tedrow et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)
A. J. Rose et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research
Peter C. Austin
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION (2009)
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence
Yoko Miyasaka et al.
CIRCULATION (2006)
Epidemiology and determinants of outcome of admissions for atrial fibrillation in the United States from 1996 to 2001
F Khairallah et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Obesity and the risk of new-onset atrial fibrillation
TJ Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
分享论文
